Hepatitis C virus (HCV) among injecting drug users (IDUs) is one of the European Union's (EU) major public health problems. This review examines the current state of knowledge regarding HCV among IDUs in EU countries. Studies published between January 1990 and December 2000, were identified through a computerized search (MEDLINE and EMBASE). Ninety-eight studies have reported prevalence for HCV among groups of IDUs in all EU countries except Luxembourg. The prevalence of anti-HCV ranged from 30 to 98%. Incidence rates ranged from 6 . 2 to 39 . 3 per 100 person years. This review provides a comprehensive examination of HCV infection among IDUs in the countries of the EU, and quite clearly demonstrates that the quality and epidemiological relevance of the studies published varies widely. Thus, the reported data may not reflect accurately the current or recent past prevalence of HCV among IDUs in the EU. A strategic approach to the surveillance of HCV among IDUs in the EU, utilizing robust and consistent methods, is required urgently.
INTRODUCTION
With the detection of the hepatitis B virus (HBV) in the 1960s and the hepatitis A virus in the 1970s, it became apparent that a considerable proportion of otherwise unexplained acute clinical hepatitis cases could not be classified as A or B. The great majority of blood/blood product transfusion related cases were identified as non-A, non-B hepatitis (NANBH). In 1989, investigators from the Chiron corporation identified the causative agent of these cases and named it hepatitis C virus (HCV) [1] . Since then, HCV infection has been recognized as a major health problem worldwide with an estimated 3% of the world population being infected [2] .
HCV is transmitted primarily through the parenteral route. Well-recognized modes of transmission involve blood or blood product transfusions, the sharing of injecting equipment by drug users and the use of inadequately sterilized or unsterilized equipment in the healthcare setting [3, 4] . HCV is transmitted much less commonly through unprotected sexual intercourse and from mother to child [5] .
In most developed countries, and in some developing countries, those at highest risk of acquiring HCV infection are injecting drug users (IDUs) who share equipment. In the European Union (EU), it is estimated that there are 1 . 5 million problem drug, mainly heroin, users [6] . If the spread of HCV among IDUs is to be prevented through the implementation of effective interventions, it is essential that the extent of the problem is gauged continuously. In this review, the authors report the current state of knowledge regarding the monitoring of the prevalence and incidence of HCV among IDUs in the EU. 
METHODS

Literature review
Studies published between January 1990 and December 2000 were identified through a computerized search (MEDLINE 1 and EMBASE), using relevant keywords and MeSH headings. Searches were not limited to English language publications, and additional references were selected from the bibliographies of identified articles. The search strategy identified 1411 references, of which 98 contained HCV prevalence and/or incidence data for IDUs in EU countries.
Data were recorded from the articles by means of a proforma. This was derived from the form used for the collection of data on HIV prevalence by EuroHIV (the former European Centre for the Epidemiological Monitoring of AIDS) and comprised several parameters against which the design and quality of the studies were assessed ; these included the target population, geographical coverage, recruitment site, sampling criteria and HCV testing methods.
RESULTS
Prevalence of HCV among European Union IDUs
Since the discovery of HCV, 98 published studies have examined the prevalence of the virus among groups of IDUs in all EU countries except Luxembourg ( Table 1) .
The earliest evidence of HCV among European IDUs stemmed from three studies, undertaken by researchers in Italy, The Netherlands and the UK [7] [8] [9] ; all reported the presence of HCV antibody in more than 70% of their sample population. Since then, the published literature has reported HCV antibody and/ or RNA positivity in 21 574 (71 %) of 30 359 IDU specimens (serum or saliva) tested.
The majority of studies (93) report the prevalence of antibody to HCV (anti-HCV) ; positivity indicates previous infection. The prevalence ranged from 30 to 95 % among males [10, 11] , 48 to 94 % among females [12, 13] , and 33 to 98 % among those whose gender was unspecified [14, 15] ; few studies detected anti-HCV in less than 40 % of their IDU population.
The detection of HCV RNA by molecular tests such as the polymerase chain reaction indicates the presence of acute or chronic infection. Five studies (5 . 2 %) reported the prevalence of HCV RNA in serum ; this ranged from 26 to 90% [8, [16] [17] [18] [19] .
Incidence of HCV infection among European Union IDUs
While HCV prevalence data are relatively easy to generate, the reverse applies to information about the incidence of infection. Consequently, there are few estimates of the incidence of HCV among IDUs in Europe. The first published report of HCV incidence arose from a cohort of IDUs from Amsterdam who participated in a study to assess their incidence of, and risk factors for, HIV infection. On the basis of 17 seroconvertors, observed during the period 1985-9, an incidence of 8 . 2 per 100 person years was reported [9] . Since then, the findings from a further five studies have been published [20] [21] [22] [23] [24] . Of the aggregated 337 IDUs who were initially HCV seronegative, 78 (23 %) seroconverted on follow-up ; incidence rates ranged from 6 . 2 to 39 . 3 per 100 person years ( Table 2) .
Five of the six studies were undertaken in a drug treatment environment which may have influenced the seroconversion rate. In such a setting, drug workers have an ethical obligation to provide IDUs, including study participants, with information and advice on how to prevent contracting bloodborne viruses. Accordingly, HCV incidences among IDUs in drug treatment centres may be lower than those among more representative population samples. Nonetheless, the data suggest that HCV continues to spread among Europe's IDUs despite the introduction of needle and syringe exchange schemes and other interventions.
Risk factors for incident HCV among European Union IDUs
The paucity of cohort studies and their small sample sizes precludes any in-depth discussion regarding risk factors associated with HCV seroconversion. In the study based in Bassano, Italy, only two individuals seroconverted ; one had shared injecting equipment and the other had an anti-HCV positive partner [22] . Among IDUs who attended a drug treatment centre in Naples, older age and longer duration of drug use were associated with HCV seroconversion [21] . Among those who attended a needle exchange service in Malmo, Sweden, HCV seroconversion correlated with imprisonment, absence of drug-free periods and lack of needle/syringe availability [24] . Reports on the remaining three studies did not provide any information about risk factors and seroconversion.
Methodological issues
Ascertaining the prevalence and/or incidence of HCV among IDUs in the EU presents substantial methodological challenges. These include the recruitment of representative samples of an IDU population; only self-selected groups are relatively easy to access through, for example, drug treatment and needle and syringe exchange agencies. Accordingly, almost all the published studies, identified in this review, involved the adoption of a suboptimal recruitment strategy ; 74 % were based on either the testing of (i) residues of serum samples, originally taken from IDUs for other clinical purposes or (ii) samples given by consenting IDUs who had been recruited in drug treatment or prison settings (Table 3) . Only one study, conducted in Glasgow during 1990-6, used the optimal community-wide sampling approach which involves recruiting quotas of injectors from street sites, drug treatment and needle and syringe exchange centres throughout the geographical area being studied.
The majority of published studies (n=86) were carried out at a local level, usually focusing on IDU populations in major cities ; national or multipleregion studies were undertaken in nine EU countries. In most countries where more than one study was undertaken, wide variations in HCV prevalence were reported (Fig. 1) . Thus, great caution is required if national prevalences are to be extrapolated from local ones and if inter-country comparisons in prevalence are to be made.
The laboratory diagnosis of HCV has evolved considerably since the introduction of the first serological tests in 1989 [1] ; third-generation tests, which afford high sensitivity and specificity, are now available. In the studies reviewed, 22 different testing algorithms were employed (Table 4) ; screening enzyme immunoassays and confirmation immunoblot assays, of different generations, were used alone or together in various combinations. A single unconfirmed test, using a first-generation ELISA, was the most common strategy (26 . 5%), followed by testing using a single second-generation ELISA (17 . 3%) ; for seven studies, the testing algorithm was not specified. The lack of sensitivity and specificity, associated with first-generation assays, and the absence of confirmatory tests necessitates that the resulting data be interpreted with care. Furthermore, a reliable comparison of different study results should only be made if the strategy for testing is similar.
DISCUSSION
This review provides a comprehensive examination of HCV infection among selected populations of IDUs in the countries of the European Union. Several conclusions can be made. It is evident that the current state of knowledge about the prevalence and incidence of HCV among IDUs in the European Union is far from satisfactory. The quality and epidemiological relevance of the studies appraised varies widely. The results are derived primarily from studies of convenience samples that are unlikely to be representative K. Roy and others of total current, or past, IDU populations. Furthermore, information on the recent past prevalence of HCV is extremely scanty ; this may be because, (i) few studies were conducted in the mid to late 1990s, (ii) of delays associated with the publication of results, or (iii) of a lack of interest, among study investigators and/or editors, in publishing the findings of studies that seemed to be repeating work carried out in the early 1990s. The reported data, thus, may not reflect accurately the current or recent past prevalence of HCV among European Union IDUs. Nonethelessdespite the above shortcomings -the results, which were generated through the study of different populations of IDUs, recruited using different strategies in different settings and tested for HCV using different assays, indicate consistently high prevalences ; similar rates have been identified among IDUs from North America [25] , Australia [26] and Asia [27] . It is possible, however, that published data are biased in favour of high prevalences since low prevalence findings might be considered relatively uninteresting and not worthy of publication. Despite the existing data having many deficiencies, they suggest that most of the current IDU populations throughout the EU have HCV prevalences that lie within the 25-75 % range. Accordingly, HCV among IDUs is one of the EU's major public health problems. With the ever-increasing mobility of populations, including those who inject drugs, the effectiveness of HCV prevention initiatives in one EU country is important to all EU countries. Intervention programmes, in terms of their type and scale, vary geographically, as do their effectiveness in preventing HCV transmission among IDUs because of regional variations in culture, deprivation, the environment and pre-existing HCV prevalence. If interventions are to be targeted, and evaluated effectively, both nationally and internationally, it is essential that they are aligned to surveys that monitor the incidence of HCV infection. The serial cross-sectional prevalence survey -with IDUs recruited using a consistent quota sampling strategy from settings (including street sites) throughout a population -is considered, by many, to be the optimal approach to gauging HCV incidence among this group. It is appreciated, however, that major demographic changes -for example, the large-scale migration of IDUs to or from a city -can make the interpretation of data a complex exercise. An indirect measure of HCV incidence among IDUs can also be achieved through using the reported time of first injection to assess the individual's number of person years of injecting exposure; this approach is most valuable if the interval between reported injecting debut and time of sampling is short (1-2 years). Despite the benefits of the repeated cross-sectional survey approach, there are few publications to indicate that such surveillance is being conducted in the EU.
The longitudinal approach to measuring the incidence of HCV among IDUs is unpopular -as indicated by the small number of cohort studies reported in this review -because IDUs are difficult to follow-up and, almost invariably, such follow-up is conducted in a drug treatment/clinical setting where there is an ethical obligation for bloodborne virus prevention advice to be imparted to study participants. The only study, known to the authors, of HCV among IDUs that combines the scientific rigour of the community-wide sampling approach, with a longitudinal design, is currently being conducted in London (M. Hickman, personal communication).
Real-time prevalence data are also required to estimate the numbers of infected IDUs who may require anti-viral treatment and who will proceed, with or without treatment, to severe liver disease.
Accordingly, high quality information on the prevalence/incidence of HCV among IDUs is essential for those whose responsibility it is to deliver services to prevent, and care for persons with, HCV infection. Where possible, methods should be robust and consistent to enable both intra-and trans-city/region/ country comparisons tobe made. Geographically based analyses will help those responsible for delivering prevention programmes to understand the reasons for regional variations in HCV prevalence/incidence. A strategic approach to the surveillance of HCV among IDUs in the EU is required urgently.
